SCHIFF ANDREW N
Insider CIK 1172252 · SNSS 10% owner · AGRX Director, 10% owner · ADMA 10% owner · ZLTQ Director, 10% owner · ESPR 10% owner · CEMP 10% owner · TTOO 10% owner · VSAR 10% owner · DRTX 10% owner · SYRS 10% owner · ACRS Director · LOXO 10% owner · ZSAN 10% owner · ELEV 10% owner · GLUE Director · SFES.OB Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2026-06-11 | 2026-06-12 | 25,800 | — | $0 | 25,800 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2026-06-05 | 2026-06-08 | 11,580 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2026-06-05 | 2026-06-08 | 11,580 | — | $0 | 25,540 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2026-06-04 | 2026-06-08 | 10,987 | — | $0 | 10,987 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2026-06-04 | 2026-06-08 | 42,350 | — | $0 | 42,350 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2025-06-13 | 2025-06-16 | 30,700 | — | $0 | 30,700 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2025-06-06 | 2025-06-09 | 4,793 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2025-06-06 | 2025-06-09 | 4,793 | — | $0 | 13,960 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 11,580 | — | $0 | 11,580 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 42,350 | — | $0 | 42,350 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2024-06-12 | 2024-06-13 | 22,100 | — | $0 | 22,100 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2024-06-06 | 2024-06-10 | 4,793 | — | $0 | 4,793 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2024-06-06 | 2024-06-10 | 15,750 | — | $0 | 15,750 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2024-06-01 | 2024-06-04 | 4,660 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2024-06-01 | 2024-06-04 | 4,660 | — | $0 | 9,167 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2023-06-16 | 2023-06-21 | 31,238 | — | $0 | 31,238 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2023-06-14 | 2023-06-15 | 20,500 | — | $0 | 20,500 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2023-06-02 | 2023-06-05 | 4,507 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2023-06-02 | 2023-06-05 | 4,507 | — | $0 | 4,507 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2023-06-01 | 2023-06-05 | 15,750 | — | $0 | 15,750 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2023-06-01 | 2023-06-05 | 4,660 | — | $0 | 4,660 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-11-14 | 2022-11-14 | 1,371 | $17.08 | $23.4K | 434,455 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-11-11 | 2022-11-14 | 41,160 | $17.06 | $702.2K | 435,826 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-11-10 | 2022-11-14 | 11,395 | $17.02 | $193.9K | 476,986 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-26 | 2022-10-26 | 14,540 | $17.01 | $247.3K | 488,381 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-25 | 2022-10-26 | 12,018 | $17.02 | $204.5K | 502,921 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-24 | 2022-10-26 | 14,616 | $17.01 | $248.6K | 514,939 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-18 | 2022-10-19 | 32,093 | $16.89 | $542.1K | 529,555 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-17 | 2022-10-19 | 19,944 | $16.05 | $320.1K | 561,648 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-07 | 2022-10-11 | 7,324 | $16.16 | $118.4K | 581,592 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-06 | 2022-10-06 | 37,839 | $16.54 | $625.9K | 588,916 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-10-04 | 2022-10-06 | 7,700 | $16.01 | $123.3K | 626,755 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2022-06-17 | 2022-06-22 | 15,619 | — | $0 | 15,619 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | S Sale | 2022-06-17 | 2022-06-21 | 19,565 | $15.14 | $296.2K | 0 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2022-06-15 | 2022-06-16 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2022-06-03 | 2022-06-06 | 3,356 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2022-06-03 | 2022-06-06 | 3,356 | — | $0 | 19,565 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2022-06-02 | 2022-06-06 | 4,507 | — | $0 | 4,507 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2022-06-02 | 2022-06-06 | 15,750 | — | $0 | 15,750 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion deriv | 2021-06-29 | 2021-07-01 | 8,000,000 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion deriv | 2021-06-29 | 2021-07-01 | 1,936,834 | — | $0 | 0 | SEC↗ |
| ELEV Elevation Oncology, Inc. | P Buy | 2021-06-29 | 2021-07-01 | 187,500 | $16.00 | $3.00M | 2,834,910 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion | 2021-06-29 | 2021-07-01 | 458,360 | — | $0 | 2,647,410 | SEC↗ |
| ELEV Elevation Oncology, Inc. | C Conversion | 2021-06-29 | 2021-07-01 | 1,893,232 | — | $0 | 2,189,050 | SEC↗ |
| ELEV Elevation Oncology, Inc. | A Award deriv | 2021-06-24 | 2021-06-28 | 31,238 | — | $0 | 31,238 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2021-06-23 | 2021-06-25 | 47,132 | — | $0 | 47,132 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2021-06-03 | 2021-06-04 | 3,356 | — | $0 | 3,356 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2021-06-03 | 2021-06-04 | 12,250 | — | $0 | 12,250 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2020-06-06 | 2020-06-08 | 7,333 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2020-06-06 | 2020-06-08 | 7,333 | — | $0 | 16,209 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2020-06-04 | 2020-06-08 | 16,500 | — | $0 | 16,500 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise deriv | 2020-03-02 | 2020-03-04 | 8,876 | — | $0 | 0 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2020-03-02 | 2020-03-04 | 8,876 | — | $0 | 8,876 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | M Exercise | 2020-03-02 | 2020-03-04 | 8,876 | — | $0 | 8,876 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2019-12-02 | 2019-12-06 | 689,655 | $1.45 | $1000.0K | 2,718,226 | SEC↗ |
| SNSS SUNESIS PHARMACEUTICALS IN | P Buy | 2019-07-15 | 2019-07-15 | 2,500,000 | $0.60 | $1.50M | 10,100,000 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2019-06-06 | 2019-06-10 | 7,333 | — | $0 | 7,333 | SEC↗ |
| ZSAN Zosano Pharma Corp | A Award | 2019-04-11 | 2019-04-12 | 428,571 | $3.50 | $1.50M | 2,028,571 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2018-07-10 | 2018-07-12 | 1,400,000 | $179.43 | $251.20M | 2,038,920 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2018-06-07 | 2018-06-08 | 8,000 | — | $0 | 8,000 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-12-19 | 2017-12-20 | 250,000 | $80.50 | $20.13M | 3,438,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | S Sale | 2017-11-22 | 2017-11-27 | 500,000 | $75.00 | $37.50M | 3,688,920 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | P Buy | 2017-08-16 | 2017-08-16 | 108,601 | $23.02 | $2.50M | 634,455 | SEC↗ |
| ACRS Aclaris Therapeutics, Inc. | A Award deriv | 2017-08-09 | 2017-08-14 | 16,000 | — | $0 | 16,000 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | D To issuer deriv | 2017-04-28 | 2017-05-01 | 1,589 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | D To issuer | 2017-04-28 | 2017-05-01 | 13,137 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | D To issuer | 2017-04-28 | 2017-05-01 | 1,597,742 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2017-01-10 | 2017-01-12 | 160,000 | $31.00 | $4.96M | 4,188,920 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2016-08-11 | 2016-08-12 | 230,769 | $36.42 | $8.40M | 1,597,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2016-08-11 | 2016-08-12 | 269,231 | $36.37 | $9.79M | 1,828,511 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion deriv | 2016-07-06 | 2016-07-06 | 1,907,122 | — | $0 | 0 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | C Conversion | 2016-07-06 | 2016-07-06 | 508,565 | — | $0 | 508,565 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | P Buy | 2016-07-06 | 2016-07-06 | 400,000 | $12.50 | $5.00M | 908,565 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award | 2016-06-16 | 2016-06-23 | 6,199 | — | $0 | 13,137 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | J Other | 2016-06-02 | 2016-06-03 | 400,000 | — | $0 | 2,583,797 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2016-05-17 | 2016-05-19 | 232,558 | $21.50 | $5.00M | 4,028,920 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-12-11 | 2015-12-15 | 200 | $27.50 | $5.5K | 3,796,362 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2015-12-09 | 2015-12-09 | 307,692 | $9.75 | $3.00M | 2,830,992 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2015-12-08 | 2015-12-09 | 24,600 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2015-12-08 | 2015-12-09 | 700 | — | $0 | 1,589 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2015-12-08 | 2015-12-09 | 700 | — | $0 | 32,238 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-12-08 | 2015-12-09 | 25,300 | $30.17 | $763.3K | 6,938 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2015-12-08 | 2015-12-09 | 24,600 | — | $0 | 31,538 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2015-12-07 | 2015-12-09 | 5,400 | — | $0 | 24,600 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2015-12-07 | 2015-12-09 | 2,082 | — | $0 | 700 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2015-12-07 | 2015-12-09 | 5,400 | — | $0 | 12,338 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2015-12-07 | 2015-12-09 | 2,082 | — | $0 | 14,420 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-12-07 | 2015-12-09 | 7,482 | $30.01 | $224.5K | 6,938 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-23 | 2015-11-24 | 100,000 | $31.46 | $3.15M | 2,097,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-20 | 2015-11-24 | 155,992 | $30.27 | $4.72M | 2,197,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-19 | 2015-11-20 | 4,719 | $31.39 | $148.1K | 2,353,734 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-19 | 2015-11-20 | 45,281 | $29.59 | $1.34M | 2,358,453 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-18 | 2015-11-20 | 41,181 | $30.78 | $1.27M | 2,556,561 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2015-11-18 | 2015-11-20 | 152,827 | $31.10 | $4.75M | 2,403,734 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-17 | 2015-11-19 | 265,000 | $26.50 | $7.02M | 3,796,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-13 | 2015-11-16 | 1,955 | $27.47 | $53.7K | 3,531,182 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2015-11-12 | 2015-11-16 | 76,714 | $27.65 | $2.12M | 3,529,207 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award | 2015-07-22 | 2015-07-24 | 790 | — | $0 | 6,938 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award | 2015-06-17 | 2015-06-22 | 4,996 | — | $0 | 6,148 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | A Award deriv | 2015-06-10 | 2015-06-10 | 14,000 | — | $0 | 14,000 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-24 | 2015-04-27 | 5,743 | $108.00 | $620.2K | 1,898,851 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-24 | 2015-04-27 | 61,726 | $106.10 | $6.55M | 1,837,125 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | S Sale | 2015-04-23 | 2015-04-27 | 150,000 | $109.10 | $16.36M | 1,904,594 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2015-01-27 | 2015-01-29 | 145,000 | $17.25 | $2.50M | 2,139,568 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | P Buy | 2015-01-23 | 2015-01-27 | 811,966 | $5.85 | $4.75M | 2,983,797 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2014-09-02 | 2014-09-04 | 5,165 | — | $0 | 4,371 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise deriv | 2014-09-02 | 2014-09-04 | 30,000 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2014-09-02 | 2014-09-04 | 5,165 | — | $0 | 36,317 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | X Exercise | 2014-09-02 | 2014-09-04 | 30,000 | — | $0 | 31,152 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2014-09-02 | 2014-09-04 | 35,165 | $22.55 | $793.0K | 1,152 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 2,967,033 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion deriv | 2014-08-12 | 2014-08-14 | 549,851 | — | $0 | 0 | SEC↗ |
| TTOO T2 Biosystems, Inc. | C Conversion | 2014-08-12 | 2014-08-14 | 2,068,755 | — | $0 | 2,068,755 | SEC↗ |
| TTOO T2 Biosystems, Inc. | P Buy | 2014-08-12 | 2014-08-14 | 454,545 | $11.00 | $5.00M | 2,523,300 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 506,960 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion deriv | 2014-08-06 | 2014-08-06 | 2,343,749 | — | $0 | 0 | SEC↗ |
| LOXO Loxo Oncology, Inc. | C Conversion | 2014-08-06 | 2014-08-06 | 2,850,709 | — | $0 | 3,039,416 | SEC↗ |
| LOXO Loxo Oncology, Inc. | P Buy | 2014-08-06 | 2014-08-06 | 413,077 | $13.00 | $5.37M | 3,452,493 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award deriv | 2014-05-30 | 2014-06-03 | 30,000 | — | $0 | 30,000 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | P Buy | 2014-05-23 | 2014-05-28 | 1,333,333 | $6.00 | $8.00M | 2,171,831 | SEC↗ |
| AGRX AGILE THERAPEUTICS INC | A Award deriv | 2014-05-22 | 2014-05-27 | 21,000 | — | $0 | 21,000 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 3,528 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | J Other | 2014-05-20 | 2014-05-22 | 745,730 | — | $0 | 2,280,175 | SEC↗ |
| TRXC TRANSENTERIX INC. | P Buy | 2014-04-21 | 2014-04-23 | 1,037,767 | $4.00 | $4.15M | 8,335,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 14,222,222 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 403,704 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 1,479,993 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 654,796 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion deriv | 2014-03-26 | 2014-03-27 | 5,486,820 | — | $0 | 0 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 1,236,715 | — | $0 | 1,271,819 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 35,104 | — | $0 | 35,104 | SEC↗ |
| VSAR Versartis, Inc. | P Buy | 2014-03-26 | 2014-03-27 | 60,000 | $21.00 | $1.26M | 1,994,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 477,115 | — | $0 | 1,934,568 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 56,939 | — | $0 | 1,457,453 | SEC↗ |
| VSAR Versartis, Inc. | C Conversion | 2014-03-26 | 2014-03-27 | 128,695 | — | $0 | 1,400,514 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-21 | 2014-03-21 | 2,649 | $15.57 | $41.2K | 3,030,175 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | S Sale | 2014-03-20 | 2014-03-21 | 98,000 | $15.74 | $1.54M | 3,032,824 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,715 | — | $0 | 0 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 994,305 | — | $0 | 2,597,742 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 4,697 | — | $0 | 4,697 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 2,398 | — | $0 | 2,398 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | J Other | 2014-01-23 | 2014-01-27 | 1,152 | — | $0 | 1,152 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion | 2013-12-06 | 2013-12-10 | 12,401,764 | — | $0 | 36,490,260 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | S Sale | 2013-11-14 | 2013-11-15 | 575,000 | $12.22 | $7.03M | 3,597,742 | SEC↗ |
| ADMA ADMA BIOLOGICS, INC. | P Buy | 2013-10-22 | 2013-10-23 | 411,765 | $8.50 | $3.50M | 3,620,143 | SEC↗ |
| SFES.OB SafeStitch Medical, Inc. | P Buy deriv | 2013-09-03 | 2013-09-05 | 1,240,176 | $4.00 | $4.96M | 1,240,176 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | J Other deriv | 2013-07-01 | 2013-07-01 | 497,666 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | C Conversion deriv | 2013-07-01 | 2013-07-01 | 1,816,475 | — | $0 | 0 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | J Other deriv | 2013-07-01 | 2013-07-01 | 71,237 | — | $0 | 71,237 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | P Buy | 2013-07-01 | 2013-07-01 | 238,119 | $14.00 | $3.33M | 2,054,594 | SEC↗ |
| ESPR Esperion Therapeutics, Inc | C Conversion | 2013-07-01 | 2013-07-01 | 1,816,475 | — | $0 | 1,816,475 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award deriv | 2013-06-19 | 2013-06-20 | 30,000 | — | $0 | 30,000 | SEC↗ |
| TRXC.OB TRANSENTERIX INC. | C Conversion deriv | 2012-07-24 | 2013-12-10 | 1,240,176 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion deriv | 2012-07-24 | 2012-07-25 | 16,157,707 | — | $0 | 0 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | P Buy | 2012-07-24 | 2012-07-25 | 1,111,111 | $9.00 | $10.00M | 3,130,824 | SEC↗ |
| DRTX Durata Therapeutics, Inc. | C Conversion | 2012-07-24 | 2012-07-25 | 2,019,713 | — | $0 | 2,019,713 | SEC↗ |
| ZLTQ Zeltiq Aesthetics Inc | A Award deriv | 2012-06-14 | 2012-06-18 | 9,536 | — | $0 | 9,536 | SEC↗ |
| CEMP CEMPRA, INC. | P Buy | 2012-02-07 | 2012-02-09 | 1,213,663 | $6.00 | $7.28M | 3,293,060 | SEC↗ |